Biotech Values

[ghmm]

If you are a bio/pharma company with cash looking to expand your pipeline when do you buy? It seems there is no rush in this market.

JJ Bienaime, (IMO an excellent) CEO of Biomarin, which has been actively looking for a deal has said on recent presentations the prices are getting cheaper and cheaper.

My guess is the first to go would be private companies with near-to-market products.

I wonder if anyone has a list of public (I imagine private are hard to come by) companies with products in Phase 3 or beyond who don't have the resources to bring the product to market. I can think of a couple but don't like them for various reasons.